- SLS009 Demonstrated Promising Efficacy in Phase 1 Study with 36.4% Clinical Response (ORR) in r/r Peripheral T-cell Lymphomas (PTCL); ORR in r/r PTCL Patients with Standard of Care is 25.8% - - Fast Track Designation Accelerates SLS009's Path to U.S. FDA Submission for Treatment of r/r PTCL - NEW… Read More..

MIAMI, FL / ACCESSWIRE / October 25, 2023 / SKYX Platforms Corp. (NASDAQ:SKYX) (d/b/a "SKYX Technologies") a highly disruptive platform technology company with over 77 pending and issued patents globally, and over 60 lighting and home décor websites with a mission to make homes and buildings become safe and smart… Read More..

Porter Hospital Becomes First Facility in Denver to Give Chronic Low Back Pain Patients Access to Revolutionary Nociscan Technology That Measures Biomarkers to Pinpoint the Source of Pain George Frey, MD Becomes Aclarion’s First KOL Surgeon to Onboard a Hospital MRI to add Nociscan Data to his Treatment Decisioning Process… Read More..